Voythos

Market position

Voythos is an early-stage, pre-seed to seed-stage company in AI-based cardiovascular informatics, recognized regionally through Houston and Rice University innovation programs. Company-research listings name VasoGnosis, Vocaire, Voximetry and Voxel Healthcare as similar companies.

Management cites two differentiators: a focus on forecasting what will happen to a patient — patient trajectory models predicting month-to-month disease progression — rather than detecting existing disease, and the clinical insight of having a practicing vascular surgeon as a co-founder. Access to granular, non-public clinical and imaging datasets through Mayo Clinic and Northwestern Medicine partnerships is also presented as a barrier to entry.

Technology

Multimodal machine learning combining medical imaging with granular clinical data such as minute-to-minute blood pressure, heart rate and patient history. The company builds patient trajectory models intended to predict disease progression and complication risk over short and medium horizons. Training data comes from EHR-level records obtained through Mayo Clinic Platform Accelerate, Northwestern Medicine, and a purchased 1.6 million-patient dataset, with the website citing more than 500,000 longitudinal patient records. Pythia, an in-development model spanning the entire aorta, is being taken toward FDA clearance.

Go-to-market

Voythos has advanced through accelerator and health-system channels — OwlSpark at Rice, Mayo Clinic Platform Accelerate, and Techstars with Northwestern Medicine as a limited partner — using these relationships for data access, credibility and institutional integration. Its stated 2026 objective is to place the product in surgeons' hands at five to ten institutions.

Vascular and cardiovascular surgeons and the health systems and hospitals that employ them, initially those managing aortic disease patients under surveillance.

Geography

Headquartered in Houston, Texas, with a base at Rice Nexus in The Ion; clinical data partnerships span Mayo Clinic and Northwestern Medicine in the United States.

History

The company was founded by Dr. Sophia Khan, a vascular surgeon, and her husband Joe Makoid, who had spent roughly 14 years in MedTech including corporate finance and medical device sales at Johnson & Johnson and a period at C-SATS, a surgical computer-vision startup acquired by J&J. Jordan Graves, whom the founders met online, joined as CTO to add technical depth. One company profile gives a founding year of 2020. Voythos went through Rice University's OwlSpark accelerator (Class 11), won first place and $20,000 at the Lifex pitch competition, was named one of the most promising life science companies at the 2024 Texas Life Science Forum, and became a resident startup at Rice Nexus at The Ion when the hub opened in February 2025. It took part in the Mayo Clinic Platform Accelerate showcase in May 2025 and the Techstars program with Northwestern Medicine, pitching at demo day in June 2025, and presented at the 2026 MedTech Innovator Radar Forum.

Risks & controversies

Pythia is still in development and the company is pursuing FDA clearance, a regulatory dependency for commercialization. The business remains very small, with headcount listed in the 1-10 range, and its commercialization approach was still undecided as of early 2026. Model training depends on data access negotiated through institutional partners, which the CEO described as the company's biggest challenge.